MKI67 and cancer: Interestingly, we observed a reduction in the percentage of events that were cancer cells in LLC-sh21 compared with LLC-NT (17.54% LLC-NT to 11.07% LLC-sh21) replicates as well as a decreased frequency of Ki67+ proliferating cancer cells in LLC-sh21 versus LLC-NT replicates (Figs 5D and S5D, and E).